The evaluation of safety and efficacy of Favipiravir (ABIDI Pharmaceutical Co, Iran) to shorten the contagiousness in patients with mild to moderate COVID-19

Dr. Abidi pharmacutical Co.0 个研究点目标入组 126 人开始时间: 待定最近更新: 2020年11月9日

试验速览

暂无简介。

•Patients with mild to moderate COVID-19 symptoms (According to the national guidance definitions) with positive PCR test for COVID-19
•At least 18 years old
•Less than 10 days from the onset of symptoms

•History of liver disorders (specifically active liver disorders and liver dysfunction included: ALT/AST > 1.5 ULN and ALP > 2.5 ULN and total Bilirubin>1.25 ULN)
•Allergy to Favipiravir or its ingredients
•Pregnancy and lactation
•History of gastrointestinal(GI) disorders such as GI bleeding or GI inflammatory diseases or history of GI surgery that intervene in the Favipiravir absorption process
•History of active or latent tuberculosis
•Active infection other than COVID-19
•Abnormal metabolism of uric acid/ Gout
•Abnormal test results in the screening stage that need more clinical assessments
•Participation in any type of clinical trials in the last 30 days
•Any psychological disorders that affects patient compliance of the study protocol
•Any disease or disorder that investigators believed might put participants in an excess risk, if they were included
•or history of allergy to any antiviral nocleoside-analog drugs with viral RNA polymerase inhibition mechanism
•Active HBV, HCV
•HIV or any other known immunological disorders or using immunosuppressive drugs

发起方

Dr. Abidi pharmacutical Co.